Kurt Krejcy studied medicine and started his academic career at the University of Vienna, where he performed preclinical and clinical research especially in the field of cardiovascular medicine and in clinical pharmacology. He finished his specialization in Pharmacology and Toxicology in 1994 and became Assoc. Prof. in 1996. Following his academic career Kurt Krejcy worked more than 20 years in pharmaceutical industry with a strong focus on oncology and hematology. He held several international European leadership positions at Eli Lilly in clinical research and medical affairs. In addition to his scientific expertise, he has gained deep insights into health care environment across all European countries and in Middle East and Africa. He joined AOP in 2016. Kurt Krejcy studied medicine and started his academic career at the University of Vienna, where he performed preclinical and clinical research especially in the field of cardiovascular medicine and in clinical pharmacology. He finished his specialization in Pharmacology and Toxicology in 1994 and became Assoc. Prof. in 1996. Following his academic career Kurt Krejcy worked more than 20 years in pharmaceutical industry with a strong focus on oncology and hematology. He held several international European leadership positions at Eli Lilly in clinical research and medical affairs. In addition to his scientific expertise, he has gained deep insights into health care environment across all European countries and in Middle East and Africa. He joined AOP in 2016.

Cardiology